• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing

    12/12/24 5:00:00 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ONCO alert in real time by email

    Cincinnati, OH, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) (the "Company") announced that it received a letter from The Nasdaq Capital Market ("Nasdaq") on December 6, 2024 indicating that the Company's failure to file its Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the "Form 10-Q") is in violation of Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the "Rule").

    On December 10, 2024, the Company filed the Form 10-Q with the Securities and Exchange Commission.  

    This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.  

    About Onconetix, Inc.:

    Onconetix is a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men's health and oncology. Through our recent acquisition of Proteomedix, we own Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union ("EU") under the In Vitro Diagnostic Regulation ("IVDR"). We also own ENTADFI, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia ("BPH"), a disorder of the prostate. For more information, visit www.onconetix.com.

    Contact Information:

    Onconetix, Inc.

    201 E. Fifth Street, Suite 1900

    Cincinnati, OH 45202

    Phone: (513) 620-4101

    Investor Contact Information:

    Onconetix Investor Relations

    Email: [email protected]



    Primary Logo

    Get the next $ONCO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ONCO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ONCO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement

      CINCINNATI, July 16, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") and Ocuvex Therapeutics, Inc. ("Ocuvex"), a privately held biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates, today announced that they have entered into a definitive merger agreement (the "Merger Agreement"). Andrew J. Oakley, Chairman of the Board of Onconetix, stated, "We continue to believe that the proposed transaction with Ocuvex, which brings a pipeline of commercial and late clinical stage ophthalmic assets, will bring significant value for our stockholders." Anthony W. Amato, Chairman and CEO of Ocuvex, commented

      7/16/25 8:17:00 AM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel

      CINCINNATI, Ohio, June 16, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company"), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology, today reported that on June 11, 2025, the Company received a decision from the Nasdaq Hearings Panel granting the Company's request for continued listing on The Nasdaq Stock Market, subject to the Company demonstrating compliance with the Nasdaq Listing Rule 5550(a)(2) (the "Periodic Filing Listing Rule") by June 13, 2025 and the  Nasdaq Listing Rule 5250(c)(1) (the "Bid Price Listing Rule") on or before June 30, 2025. The

      6/16/25 8:22:00 AM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders

      CINCINNATI, Ohio, June 11, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company"), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology, today announced that the Company's stockholders have approved a proposal to effect a reverse split, which was voted on at the Company's 2025 special meeting of stockholders (the "Special Meeting") held on May 30, 2025, and that its Board of Directors (the "Board of Directors" or "Board") approved a 1-for-85 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on June 1

      6/11/25 11:30:00 AM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Altos Venture Ag acquired 241,514 shares, increasing direct ownership by 761% to 273,230 units (SEC Form 4)

      4 - Onconetix, Inc. (0001782107) (Issuer)

      7/16/25 4:03:52 PM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Oakley Andrew John was granted 1,709 shares (SEC Form 4)

      4 - Onconetix, Inc. (0001782107) (Issuer)

      3/25/25 3:44:38 PM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Oakley Andrew John

      3 - Onconetix, Inc. (0001782107) (Issuer)

      3/7/25 6:07:11 AM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONCO
    SEC Filings

    See more
    • Onconetix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Onconetix, Inc. (0001782107) (Filer)

      7/16/25 8:37:17 AM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconetix Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Onconetix, Inc. (0001782107) (Filer)

      6/16/25 8:40:11 AM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Onconetix Inc.

      10-Q - Onconetix, Inc. (0001782107) (Filer)

      6/12/25 5:16:56 PM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONCO
    Leadership Updates

    Live Leadership Updates

    See more
    • Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

      Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

      10/8/24 5:00:00 AM ET
      $ENTO
      $OCS
      $ONCO
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Onconetix Inc.

      SC 13G - Onconetix, Inc. (0001782107) (Subject)

      11/14/24 11:19:35 AM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Onconetix Inc.

      SC 13D - Onconetix, Inc. (0001782107) (Subject)

      10/1/24 4:35:03 PM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Onconetix Inc.

      SC 13D - Onconetix, Inc. (0001782107) (Subject)

      10/1/24 4:35:03 PM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care